BD (Becton, Dickinson and Co.) has reported a net income of $421m, or $1.45 per diluted share, for the three months ended 30 September 2024, compared to $108m, or $0.37 per diluted share, earned in the same period of 2023.
The medical technology company’s net income for the fourth quarter (Q4) of fiscal year 2024 declined by 14% compared to $487m for the third quarter of fiscal 2024 (Q3 2024).
BD reported total revenues of $5.43bn for Q4 2024, a 7% increase compared to $5.08bn for the same quarter in 2024, and a 9% rise compared to $4.99bn for Q3 2024.
The medical diagnostics provider reported total operating costs and expenses of $4.78bn for Q4 2024, a 1% rise compared to $4.73bn in Q4 2023.
The company reported income before taxes of $542m for Q4 2024, compared to $181m for the respective quarter in the previous year.
BD chairman, CEO and president Tom Polen said: “In FY24, our team advanced our strategy, continuing to shift our portfolio into higher-growth areas through new innovations and the acquisition of Edwards Lifesciences’ Critical Care product group, while leveraging our BD Excellence system to exceed our margin expansion, earnings and cash flow goals.
“Our growth strategy remains focused on delivering solutions for our customers that leverage significant shifts in technology, like biologics, AI and automation, that are revolutionizing patient care.
“Combined with accelerated operational performance through BD Excellence and strong capital deployment, we are poised to deliver continued value creation for our shareholders.”
BD reported a net income of $1.72bn, a $5.93 per diluted share, for the twelve months ended 30 September 2024, a 21% rise compared to $1.42bn, or $4.94 per diluted share, for the same period in 2023.
The company reported revenues of $20.17bn for the fiscal year 2024 (FY 2024), a 4.2% rise compared to $19.37bn for FY 2023.
The medical diagnostics provider reported income before taxes of $2.03bn for FY 2024, a 22.3% rise compared to $1.66bn for FY 2023.
Last month, BD partnered with Ypsomed, a Switzerland-based drug delivery systems developer, to advance self-injection solutions for high-viscosity biologic drugs.
